



PARABOLIC DRUGS LTD.

CIN No. : L24231CH1996PLC017755.

Ref: PDL: NOV: 2017/NC/1

Dated: 22.11.2017

Mr. Kautuk Upadhyay, Manager
The National Stock Exchange of India Limited
"Exchange Plaza", Banda Kurla Complex
Bandra East, Mumbai
Maharashtra

Sir

SUB: Non Compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 !

This is with reference to your letter No. NSE/LIST/FR/2660 dated 15 November, 2017 in regard to deficiency observed in the financial results for the Quarter/Half year ended on 30 September, 2017 with respect to the following points:

1. Reconciliation of Profit and Loss not submitted.
2. Reconciliation of Equity not submitted.

In light of the above please find enclosed a scanned copy of the Reconciliation of Profit and Loss and Reconciliation of Equity for your kind perusal.

Kindly take note and oblige.

For & On Behalf of Parabolic Drugs Limited

Sincerely

For Parabolic Drugs Limited

Company Secretary

Ishrat Gill

Company Secretary

Encl: Reconciliation of Profit and Loss & Reconciliation of Equity.



PARABOLIC DRUGS LTD.

CIN No. : L24231CH1996PLC017755.

PARABOLIC DRUGS LIMITED

Clarification for Financial Results for the quarter/half year ended 30th September, 2017


1. Reconciliation of Profit / (Loss) reported in accordance with the Indian GAAP to total comprehensive Income in accordance with the Ind AS is given below:

Particulars	Rs. In Cr.		
	Qtr ended 30.09.16	Half year ended 30.09.16	Year Ended 31.03.17
Profit /(Loss) after tax reported under previous I-GAPP	(43.12)	(120.43)	(108.07)
Actuarial (Gain) / Loss on employee defined benefit plans recognized in other Comprehensive Income	(0.05)	(0.10)	(0.21)
Net Profit / (Loss) after Tax as per Ind AS	(43.17)	(120.53)	(108.28)
Other Comprehensive Income as per Ind AS	0.05	0.10	0.21
Total Comprehensive Income as per Ind AS	(43.12)	(120.43)	(108.07)

2. Reconciliation of Equity reported in accordance with Indian GAP to equity in accordance with IND AS is given below

Particulars of Share holding	Rs. In Cr.	
	As at 30.09.2016	As at 31.03.2017
Total Equity as per India GAAP	(827.69)	(815.33)
Adjustments on account of Application of Ind AS	0.00	0.00
Total Equity as per Ind AS	(827.69)	(815.33)

For Parabolic Drugs Limited


Manav Gupta
Managing Director

